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Abstract
Objective:  Hypovitaminoses  by  virtue  of  undernourishment  still  represent  clinical
relevant diseases with a broad spectrum of symptoms. In this article, we discuss two
patients with amyotrophic lateral sclerosis (ALS/MND) exhibiting the pattern of acute
Wernicke Encephalopathy at autopsy. Therefore, we were interested in the general
prevalence of thiamine (vitamin B1) deficiency in ALS/MND patients. 
Method: We tested 122 ALS/MND patients without respective clinical symptoms for
thiamine deficiency (transketolase blood levels and thiamin-pyrophosphat-effect test)
to determine the prevalence of thiamin deficiency in ALS/MND patients. 
Results:  We found thiamine deficiency in  28% of  our  ALS/MND patients.  Among
these,  14  patients  had  slight  (41%)  and  20  patients  severe  (59%)  thiamine
deficiency. Signs of acute Wernicke encephalopathy at autopy was seen in only 8.7
% of ALS cases autopsied.
Conclusion: The two ALS/MND autopsy cases with morphological signs of Wernicke
encephalopathy  reported  here  in  detail  and  the  subsequent  analysis  of  thiamine
deficiency in 122 ALS/MND patients strongly indicate a risk of ALS/MND patients to
develop B1 deficiency probably triggering Wernicke encephalopathy in few end-stage
ALS/MND patients.
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Introduction
Thiamin (vitamin B1) deficiency is often related to malnutrition and causes severe
neurological  disorders,  i.e.  Wernicke  encephalopathy  and  Beriberi  disease  [28].
Treatment with thiamine supplementation protects from those diseases and is used
for  therapy.  Nevertheless,  thiamine  deficiency  is  underdiagnosed  especially  with
regard to 1) iatrogenic causes such as use of diuretics [1]  and chemotherapeutic
agents  [2],  2)  long  term  parenteral  application  of  carbohydrates  without
supplementation  of  thiamine,  3)  gastrointestinal  malabsorption  (gastric  banding,
chronic gastrointestinal diseases), 4) reduced intake due to alcoholism [3], dementia
[4],  or  diets [5],  5) hyperemesis gravidarum [6] and 6) increased catabolism, e.g.
caused by neoplasias [2].
Thiamine storage in liver, heart, kidney and brain lasts for a few days to maximum 2-
4 weeks in cases of deficient intake. Thiamin functions as a coenzyme for energy
metabolism  (citrate  cycle,  pentose  5-phosphate  pathway).  Accordingly,  thiamine
deficiency  leads  to  catabolism  with  reduced  synthesis  of  amino  acids,  lipids,
neurotransmitters,  collagen  and  to  an  intracerebral  lactate  acidosis  caused  by
reduced glucose utilization, finally ending in a vicious circle of decreased absorption
and metabolism of thiamine [7].
Amyotrophic lateral sclerosis (ALS/MND) is a prototype neurodegenerative disorder
of the motor neuron disease group with degeneration of anterior horn cells in the
spinal cord, motor nuclei of cranial nerves and pyramidal cells of the motor cortex
resulting in progressive paresis of skeletal muscles. The amyotrophy typically begins
focal and continuously involves more and more adjacent muscles. In the course of
the  disease,  paresis  of  diaphragm  and  intercostal  musculature  leads  to  global
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respiratory  insufficiency.  25%  of  ALS/MND  patients  present  with  paresis-related
dysphagia resulting in weight loss, malnutrition and cachexia[9]. 
The  intention  of  this  report  is  to  highlight  thiamine  deficiency  (probably  causing
Wernicke encephalopathy-related lesions) as a potential complication in the course
of ALS/MND, which was unexpectedly found at autopsy in two (= 8.7 %) patients of a
sample of 23 ALS/MND autopsy cases. To clarify its importance and to determine its
prevalence, we additionally analyzed laboratory signs of thiamine deficiency in 122
ALS/MND patients seen in the University of Ulm Neurology Department. 
Case 1
The  patient  attended  our  outpatient  clinic  reporting  the  following  symptoms:
dysarthria, dysphagia with pseudohypersalivation and an involuntary weight loss of
10 kilograms within five months.  He observed spontaneous fasciculations and an
unaccustomed  breathlessness  during  physical  stress.  At  an  external  hospital,
probable  ALS/MND was  diagnosed.  Treatment  with  riluzole  was  started  and  the
patient was sent to the University of Ulm Neurology Department for second opinion. 
Clinical  exploration  revealed a good physical  status (body mass index 27.2)  ???
months  before  death.  The  diagnosis  of  ALS/MND (for  details  see  supplement  1
material and methods) was confirmed. In the course of the disease reevaluation of
the clinical  status was carried out  to adjust  the treatment.  The patient developed
generalized muscular atrophy and paresis requiring wheel chair use and leading to
further  weight  loss (BMI 23.5).  Percutaneous endoscopic gastrostomy (PEG) and
non-invasive ventilation (NIV) were refused by the patient. Nutrition was limited to
liquid alimentation. The patient received home care until death eleven months after
his first visit. Informed consent was granted by the next of kin for an autopsy and
scientific use of the tissue obtained at autopsy.
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Neuropathological  examination  (performed  according  to  German  law)  revealed  a
normal brain weight. The sole macroscopic abnormality was a reddish coloration of
the  corpora  mamillaria  and  the  periventricular  thalamus.  The  spinal  cord  was
macroscopically unremarkable.
Microscopically, multiple fresh hemorrhages were observed in the mammillary body
and  in  the  medial  portion  of  the  thalamus  with  the  pattern  of  acute  Wernicke
encephalopathy (figure 1 a/b). Prussian blue staining did not detect siderophages
(figure 1c). As such, there was no evidence for earlier bleedings into these regions.
Fresh bleedings elsewhere in the brain indicating general agonal congestion-related
bleedings were  not  found.  A reduced number  of  spinal  cord  motor  neurons was
observed. Phospho-TDP43-(pTDP43) positive preinclusions in pyramidal neurons of
the  frontocentral  (figure  1d)  and  parietal  cortex  and  pTDP43-positive  skein-like
inclusions in few remaining ventral horn neurons of the thoracic spinal cord (figure
1e)  were  seen  providing  the  neuropathological  correlative  for  ALS/MND.  The
distribution of pTDP43 lesions represented a pattern related to ALS/MND stage 3
according  to  Brettschneider  et  al.[10].  Only  brain  and  spinal  cord  autopsy  was
permitted precluding a cause of death statement.
Case 2
At  primary  clinical  examination,  the  patient  showed  a  spastic  tetraparesis  with
enhanced tendon reflexes, beginning distal atrophies and generalized fasciculations.
Cerebral  and  spinal  MRI  was  normal.  Electromyographically  acute  and  chronic
neurogenic changes were observed. Cerebrospinal fluid analysis showed mild signs
of  inflammation  (for  details  see  supplement  1  material  and  methods).  However,
treatment  with  methylprednisolone  had  no  effect  on  the  clinical  status.  Further
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progression  led  to  severe  dysphagia,  dysarthria  and  worsening  of  the  spastic
tetraparesis with  generalized muscular atrophy.  Symptoms and course of disease
were  consistent  with  the  diagnosis  of  ALS/MND.  Wheel  chair  use  was  required.
Parenteral gastrostomy was refused. The patient died at home. Informed consent
was granted by the next of kin for an autopsy and scientific use of the tissue obtained
at autopsy.
The autopsy revealed fresh hemorrhages in  the paraventricular nucleus and mild
fresh  hemorrhages  in  the  mammillary  body  of  the  hypothalamus  (figure  1  f/g)
suggestive for acute Wernicke encephalopathy. The Prussian blue staining did not
detect  siderophages  as  signs  of  blood  resorption  (figure  1h).  Fresh  bleedings
elsewhere in the brain indicating general agonal congestion-related bleedings were
not  found.  pTDP43-positive preinclusions were found in pyramidal  neurons of the
frontocentral cortex (figure 1 i), pTDP43-positive skein-like inclusions occurred in few
remaining neurons of  the  hypoglossal  nucleus and in  the  inferior  olivary nucleus
(figure  1  j/k),  confirming  the  diagnosis  of  ALS/MND. The  distribution  of  pTDP43
lesions represented ALS/MND stage 3 according to Brettschneider et al.[10].  Only
brain and spinal cord autopsy was permitted precluding a cause of death statement.
Material and Methods
Patients
We  investigated  a  total  of  122  ALS  patients  (age  62±13  years,  62  males,  60
females), among them 22 patients with pure bulbar form, 29 patients with pure spinal
form of ALS and 71 patients with both spinal and bulbar symptoms (stated at time of
involvement). 35 ALS patients were provided with a PEG. Patients were diagnosed
according  to  the  El-Escorial-criteria[11].  All  patients  or  their  relatives  gave  their
informed consent  prior  to  the  study  that  was  performed according  to  the  ethical
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standards of  Helsinki.  Votes of  the University  of  Ulm ethics committee cover  the
clinical observations and the post-mortem analysis of donated autopsy tissue.
Diagnosis of thiamine-deficiency
Thiamine deficiency was calculated in a two-step procedure:  basal  activity of  the
erythrocyte  Transketolase  (TK,  2  ml  EDTA blood,  spectroscopy,  reference range
between 42 and 69 U/l, Synlab laboratory)  and measurement of  TK-activity  after
addition  of  coenzyme  thiamine-pyrophosphat  in  vitro  (=  TPP-effect;  two  blood
samples  were  obtained  for  each  patient:  one  before  stimulation  with  coenzyme
thiamin-pyrophosphate, a second one  ??? min. after stimulation; 2ml EDTA blood,
photometry, Synlab laboratory). In case of thiamine deficiency, basal TK-activity rises
after addition of TPP. The percentage of activation of TK by thiamine pyrophosphate
is normal in the range of 0-15%; an increase of the TPP-effect >15% indicates mild
and >20% severe thiamine deficiency[12,13].
Apart from thiamine deficiency, diabetes mellitus, liver diseases accompanied with
elevated transaminases and medication with diuretics and antacida were also able to
influence  transketolase  activity.  For  this  reason,  it  was  essential  to  combine
measurement  of  transketolase  activity  with  analysis  of  the  enzyme-activity  after
addition  of  TPP to  saturate  the  TK with  thiamine leading to  maximum functional
capacity of the enzyme (TPP-effect).
A reference group was not studied because we focused on ALS/MND patients to
determine  their  prevalence  of  thiamine  deficiency  and  to  estimate  whether
supplementation of thiamine is required. Patients attending a neurological hospital
often belong to the well known risk groups such as elderly and/or demented persons,
alcoholics, and patients with catabolism. Therefore, a control group of patients seen
in a neurological hospital would represent a biased sample. Moreover, the thiamine
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status in random samples of defined populations is well known from other studies
[14-18]. Therefore, we refer to these studies to interpret the prevalence of thiamin
deficiency found in our ALS/MND sample.
Statistical analyses
Statistical  analyses were performed using the software  SigmaStat,  3.5.  Values of
p<0.05 were set as statistical relevant. Comparison of groups was performed by t-
test/ANOVA.
Results
We found  a  TPP-effect  in  34  (28%)  out  of  122  ALS patients.  Among these,  14
patients  had  mild  (41%)  and  20  patients  severe  (59%)  thiamine  deficiency  as
indicated by TPP-effect of 16-20% for mild thiamine deficiency and higher than 20%
for severe thiamin deficiency. Interestingly, none of these patients showed symptoms
of  Wernicke  encephalopathy  or  Beriberi  disease.  As  chronic  alcohol  abuse  is  a
possible  risk  factor  for  thiamine  deficiency,  we  screened  our  patient  files  for
information  about  alcohol  intake  and  laboratory  liver  parameters  (Alanin-
Aminotransferase, Aspartat-Aminotransferase, Gamma-Glutamyl-Transferase, mean
corpuscular  volume).  Only ALS/MND patients without  a history of  alcoholism and
without  laboratory  signs  of  liver  dysfunction  were  considered  for  assessing  the
prevalence of thiamine-deficiency in this study.
As patients with primarily bulbar symptoms are predestined for malnourishment, we
anticipated higher prevalence of thiamine deficits in this ALS subgroup than in those
patients  presenting  mainly  with  myatrophies  of  the  limbs. Contrary to our
expectations, this was not the case (p=0.46). In the subgroup of the bulbar (18%)
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versus spinal form (21%) of ALS, no relation was found between thiamine deficiency
and the severity of ALS symptoms (p=0.48), graduated by the ALS/MND-functional
rating score ALS-FRS-R[19]. Out of the PEG-provided patients, 25% had thiamine
deficiency as well; comparison between PEG-provided patients with dysphagia and
patients  with  dysphagia  without  PEG  showed  no  statistical  significance  in
development of thiamine deficiency (p=0.97). 
Discussion
Here,  we  report  morphological  signs  of  acute  Wernicke  encephalopathy  in  two
patients  with  ALS/MND,  approved  by  autopsy.  Among  our  ALS  postmortem
examinations (n=23), we detected Wernicke encephalopathy-indicative abnormalities
in only two out of 23 (8.7%) ALS/MND cases. In spite of dysphagia, both patients
refused  parenteral  gastrostomy.  Both  of  them  died  at  home,  precluding  clinical
investigation shortly before death to identify symptoms of Wernicke encephalopathy.
Home care also explains the missing TK and TPP-effect data for both of the patients.
However, diagnosis and herewith combined prevalence of Wernicke encephalopathy
has  been  gleaned  mostly  from  retrospective  autopsy  studies  and  the  latter  is
probably underestimated at 2%[20]. Only a fraction of cases (approximately 15%) are
diagnosed  antemortem  and  represent  cases  with  the  typical  clinical  signs  of
Wernicke  encephalopathy[21].  Except  for  alcohol  abuse  cases,  Wernicke
encephalopathy is usually not recognized before autopsy. 
Importantly,  the classical  clinical  triad of  Wernicke encephalopathy (mental  status
changes, ophthalmoplegia and gait ataxia) is only present in ~ 10% of cases[20].
Moreover,  ophthalmoplegia  remains  only  one  of  numerous  ocular  findings  that
include nystagmus, sixth nerve palsy, ptosis, retinal hemorrhage, papilloedema, and
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(less  frequently)  anisocoria  or  miosis[27].  Moreover,  neither  diagnostic  tool  (MRI,
blood levels) can confirm the diagnosis of Wernicke encephalopathy on its own [27].
Our finding that 28% of the ALS/MND patients admitted to the University of  Ulm
Neurology department exhibit laboratory signs of thiamine deficiency without clinical
symptoms  indicates  that  ALS/MND  patients  are  at  risk  for  developing  Wernicke
encephalopathy. A possible explanation may be malnutrition due to dysphagia and
waiving parenteral gastrostomy as in the two cases reported here. However, as there
was no different prevalence between the bulbar and the spinal form of ALS/MND and
no relation of thiamine deficiency with the severity of respective ALS/MND symptoms,
our  data  suggest  in  agreement  with  the  literature  (Zitate!!!)  no  existing  reliable
predictor for the development of thiamine deficiency. 
Interestingly, Meiniger et al. (Zitation fehlt!) investigated a large cohort of ALS/MND
patients postmortem and found pulmonary insufficiency due to pneumonia to be the
most  frequent  cause of  death in  their  samples.  The second cause of  death was
sudden death that was hypothezised to be a consequence of autonomic dysfunction.
As Wernicke encephalopathy neuropathologically affects the hypothalamus and is
consecutively able to lead to  autonomic (particularly cardial) dysfunctions that are
known  to  be  frequent  in  ALS  patients,  a  connection  between  these  two
pathomechanisms may be plausible. 
As a clinical consequence of our finding of thiamine-deficiency in 28 % of ALS/MND
patients it appears to be recommendable for clinical practice to pay attention to those
patients  being  part  of  the  well  known  risk  groups  to  develop  Wernicke
encephalopathy now including also ALS/MND patients that are listed in table 1.
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Table 1:  Risk factors for the development of thiamine deficiency either caused by
reduced intake or by diminished absorption.
risk factor Reference
alcohol abuse [2]
hyperemesis gravidarum [6]
Diarrhea [22]
gastrointestinal diseases with malabsorption [23]
gastrointestinal surgery [24]
cancer diseases [2]
anorexia nervosa / diets [5]
specific medication (diuretics and chemotherapeutics) [1,2]
magnesium depletion [25]
carbohydrate intake / parenteral nutrition [26]
elderly people (dementia) [4]
ALS/MND this study
In a second step, the clinician should be aware to symptoms of thiamine deficiency
(that can be absent as stated above). Both aspects – the affiliation to a risk group as
well as potential clinical symptoms - should lead to assess thiamine levels at a low
threshold. Patients suffering from chronic progressive diseases like ALS/MND should
be informed about thiamine deficiency when diagnosed as a potential complication
and  about  its  clinical  manifestations  that  can  present  beyond  Wernicke
encephalopathy  (polyneuropathy,  high-output  congestive  heart  failure  with  and
without  edema,  gastrointestinal  discomfort  like  vomiting,  abdominal  pain,  lactate
acidosis,  and  Marchiafava-Bignami  syndrome)[28].  Additionally,  the  possible  fatal
outcome ought to be discussed so that the ALS/MND-patient can decide in favour or
against supplementation (for application schema, see table 2).  
Table  2:  EFNS  guidelines  for  diagnosis,  therapy  and  prevention  of  Wernicke
encephalopathy[29].
Abbreviations: WE = Wernicke encephalopathy; GPP = good practice point. 
1.) The clinical diagnosis of WE should take into account the different presentations of clinical signs 
between alcoholics and non alcoholics (Recommendation Level C); although prevalence is higher in 
alcoholics, WE should be suspected in all clinical conditions which could lead to thiamine deficiency 
(good practice point – GPP).
2.) The clinical diagnosis of WE in alcoholics requires two of the following four signs (Level B):
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     (i) dietary deficiencies 
     (ii) eye signs 
     (iii) cerebellar dysfunction 
     [12] either an altered mental state or mild memory impairment 
3.) Thiamine in blood sample should be measured immediately before its administration (GPP).
4.) MRI should be used to support the diagnosis of acute WE both in alcoholics and non alcoholics 
(Level B).
5.) Thiamine is indicated for the treatment of suspected or manifest WE. It should be given before any 
carbohydrate, 200 mg thrice daily, preferably intravenously (Level C).
6.) The overall safety of thiamine is very good (Level B).
7.) After bariatric surgery, follow-up of thiamine status for at least 6 months (Level B) and parenteral 
thiamine supplementation (GPP) is recommended.
8.) Parenteral thiamine should be given to all at-risk subjects admitted to the Emergency Room (GPP).
9.) Patients dying from symptoms suggesting WE should have an autopsy (GPP).
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Figure legends
Figure  1 a,  b:  Multiple  fresh  hemorrhages in  the  mammillary  body of  the  case  1 hypothalamus
exhibiting  the  pattern  of  Wernicke  encephalopathy.  c:  The  prussian  blue  staining  did  not  detect
siderophages as signs of resorption. d: Phospho-TDP43-(pTDP43) positive preinclusions were found
in pyramidal neurons of the frontocentral cortex. e: pTDP43-positive skein-like inclusions occurred in
few remaining ventral horn neurons of the thoracic spinal cord confirming the clinical diagnosis of
amyotrophic lateral sclerosis. f, g: Fresh hemorrhages in the paraventricular nucleus and single fresh
hemorrhages in the mammillary body of case 2 hypothalamus. h: The prussian blue staining did not
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detect siderophages as signs of resorption. i: pTDP43-positive preinclusions were found in pyramidal
neurons  of  the  frontocentral  cortex.  j,  k:  pTDP43-positive  skein-like  inclusions  occurred  in  few
remaining neurons of  the hypoglosseal  nucleus  and in  the  inferior  olivary  nucleus confirming the
clinical diagnosis of amyotrophic lateral sclerosis.
Stainings: a, b, f, g: hematoxilin & eosin; c, h: Prussian blue; d, e, I, j, k: Immunohistochemistry with
antibodies  directed  against  pTDP43  (pS409/410-2,  Cosmo  Bio  Co.,  Ltd,  Tokyo,  Japan,  1/10000,
microwave pretreatment). Visualization by using biotinylated secondary antibodies, ABC-complex and
diaminobecindine-HCl (Vector, Burlingame, USA).
Calibration bar in k corresponds to: a, f: 800µm; b, c: 160µm; d, e, g-k: 15µm.
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